Evidence map›Paper›PMID 29540217›Full record

ArticleCardiovascular diabetology2018

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA

Julio Rosenstock, Vlado Perkovic, John H Alexander, Mark E Cooper, Nikolaus Marx, Michael J Pencina, Robert D Toto, Christoph Wanner, Bernard Zinman, David Baanstra and 8 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 4 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 5 countries.

Julio RosenstockDallas Diabetes Research Center at Medical City, 7777 Forest Lane, Suite C-685, Dallas, TX, 75230, USA. juliorosenstock@dallasdiabetes.com.
Vlado PerkovicThe George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
John H AlexanderDuke Clinical Research Institute, Duke Health, Durham, NC, USA.
Mark E CooperHead of Diabetes, Monash University, Melbourne, VIC, Australia.
Nikolaus MarxDepartment of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
Michael J PencinaDuke Clinical Research Institute, Duke Health, Durham, NC, USA.
Robert D TotoUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.
Christoph WannerDept of Medicine, Würzburg Univ Clinic, Würzburg, Germany.
Bernard ZinmanLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.
David BaanstraBoehringer Ingelheim bv, Alkmaar, The Netherlands.
Egon PfarrBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Michaela MattheusBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Uli C BroedlBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Hans-Juergen WoerleUlm University, Ulm, Germany.
Jyothis T GeorgeBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Maximilian von EynattenBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Darren K McGuireDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
CARMELINA® investigators
Boehringer Ingelheim (Germany) · DEClinical Research Institute · USThe University of Texas Southwestern Medical Center · USBoehringer Ingelheim (Netherlands) · NLDallas Diabetes Research Center · USMonash University · AUThe George Institute for Global Health · AUUniversitätsklinikum Aachen · DEUniversität Ulm · DEUniversity of Toronto · CAUniversity of Würzburg · DE

Funding

Pilot and Feasibility ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 to 2025
$4.9M
NIDDK NIH HHS P30 DK020572
6 · The paper itself

Abstract

backgroundCardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to uncertainty regarding their kidney efficacy and safety. The CARMELINA

methodsCARMELINA

resultsBetween July 2013 and August 2016, 6980 patients were randomized and took ≥ 1 dose of study drug (40.6, 33.1, 16.9, and 9.4% from Europe, South America, North America, and Asia, respectively). At baseline, mean ± SD age was 65.8 ± 9.1 years, HbA1c 7.9 ± 1.0%, BMI 31.3 ± 5.3 kg/m

conclusionsCARMELINA

Indexed as

AgedBiomarkersBlood GlucoseCardiovascular DiseasesCause of DeathDiabetes Mellitus, Type 2Diabetic NephropathiesDipeptidyl-Peptidase IV InhibitorsDisease ProgressionDouble-Blind MethodFemaleGlomerular Filtration RateGlycated HemoglobinHumansKidneyKidney Failure, ChronicBiomarkersBlood GlucoseDipeptidyl-Peptidase IV InhibitorsGlycated Hemoglobinhemoglobin A1c protein, humanLinagliptinCardiovascular diseasesClinical trial, phase IVDiabetes mellitus, type 2Diabetic nephropathiesDipeptidyl-peptidase IV inhibitorsLinagliptinResearch designTreatment outcome

Identifiers

PMID29540217
PMCPMC5870815
OpenAlexW2804712568

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.